These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 17889463

  • 41. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
    Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S.
    Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
    [Abstract] [Full Text] [Related]

  • 42. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women.
    Yu H, Racketa J, Chines AA, Mirkin S.
    Climacteric; 2013 Apr; 16(2):252-7. PubMed ID: 23035721
    [Abstract] [Full Text] [Related]

  • 43. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial.
    Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC.
    Obstet Gynecol; 2007 Mar; 109(3):588-96. PubMed ID: 17329509
    [Abstract] [Full Text] [Related]

  • 44. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF, Schmelter T, Schaefers M, Gerlinger C, Gude K.
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [Abstract] [Full Text] [Related]

  • 45. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens.
    Utian WH, Lederman SA, Williams BM, Vega RY, Koltun WD, Leonard TW.
    Obstet Gynecol; 2004 Feb; 103(2):245-53. PubMed ID: 14754691
    [Abstract] [Full Text] [Related]

  • 46. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
    Valiati B, Capp E, Edelweiss MI, de Freitas FM, Wender MC.
    Maturitas; 2009 Jan 20; 62(1):81-4. PubMed ID: 19097715
    [Abstract] [Full Text] [Related]

  • 47. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
    Palombo-Kinne E, Schellschmidt I, Schumacher U, Gräser T.
    Contraception; 2009 Apr 20; 79(4):282-9. PubMed ID: 19272497
    [Abstract] [Full Text] [Related]

  • 48. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J.
    J Clin Oncol; 2006 Aug 20; 24(24):3991-6. PubMed ID: 16921052
    [Abstract] [Full Text] [Related]

  • 49. Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy.
    Lantto H, Haapalahti P, Tuomikoski P, Viitasalo M, Väänänen H, Sovijärvi AR, Ylikorkala O, Mikkola TS.
    Menopause; 2012 Jan 20; 19(1):82-8. PubMed ID: 21934534
    [Abstract] [Full Text] [Related]

  • 50. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial.
    Palacios S, Wildt L, Parke S, Machlitt A, Römer T, Bitzer J.
    Eur J Obstet Gynecol Reprod Biol; 2010 Mar 20; 149(1):57-62. PubMed ID: 19969409
    [Abstract] [Full Text] [Related]

  • 51. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women.
    Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, Studd J.
    Menopause Int; 2009 Jun 20; 15(2):63-9. PubMed ID: 19465671
    [Abstract] [Full Text] [Related]

  • 52. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief.
    Panay N, Ylikorkala O, Archer DF, Gut R, Lang E.
    Climacteric; 2007 Apr 20; 10(2):120-31. PubMed ID: 17453860
    [Abstract] [Full Text] [Related]

  • 53. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
    Mizunuma H.
    Climacteric; 2011 Oct 20; 14(5):581-9. PubMed ID: 21848497
    [Abstract] [Full Text] [Related]

  • 54. Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study.
    Winther K, Rein E, Hedman C.
    Climacteric; 2005 Jun 20; 8(2):162-70. PubMed ID: 16096172
    [Abstract] [Full Text] [Related]

  • 55. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA, TOTAL Study Investigators Group.
    BJOG; 2007 Dec 20; 114(12):1522-9. PubMed ID: 17995496
    [Abstract] [Full Text] [Related]

  • 56. Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial.
    Levine DW, Dailey ME, Rockhill B, Tipping D, Naughton MJ, Shumaker SA.
    Psychosom Med; 2005 Dec 20; 67(1):98-104. PubMed ID: 15673630
    [Abstract] [Full Text] [Related]

  • 57. Acupuncture for postmenopausal hot flashes.
    Nir Y, Huang MI, Schnyer R, Chen B, Manber R.
    Maturitas; 2007 Apr 20; 56(4):383-95. PubMed ID: 17182200
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women.
    Rozenbaum H, Chevallier O, Moyal M, Durand G, Perineau M, This P, Aerodiol study group.
    Climacteric; 2002 Sep 20; 5(3):249-58. PubMed ID: 12419083
    [Abstract] [Full Text] [Related]

  • 59. Efficacy and safety of a special extract of Rheum rhaponticum (ERr 731) in perimenopausal women with climacteric complaints: a 12-week randomized, double-blind, placebo-controlled trial.
    Heger M, Ventskovskiy BM, Borzenko I, Kneis KC, Rettenberger R, Kaszkin-Bettag M, Heger PW.
    Menopause; 2006 Sep 20; 13(5):744-59. PubMed ID: 16894335
    [Abstract] [Full Text] [Related]

  • 60. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints.
    Gräser T, Römer T, Wiedey KD, Janaud A.
    Climacteric; 2001 Dec 20; 4(4):332-42. PubMed ID: 11770190
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.